Nonmyeloablative allogeneic immunotherapy for solid tumors

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 459-475

  Childs, Richard W ^a   Barrett, John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Allogeneic stem cell transplantation; Graft versus leukemia; Graft versus tumor; Nonmyeloablative transplant; Renal cell carcinoma

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; THIOTEPA;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOSARCOMA; CHIMERA; CYTOPATHOGENIC EFFECT; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA SYSTEM; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; NATURAL KILLER CELL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VEIN OCCLUSION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 1542299089     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104511     Document Type: Review

References (77)

1. Thomas ED, Lochte HL Jr, Cannon JH, et al. 1959. Supra-ethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Invest 38:1709-16
2. Barrett J, Childs R. 2000. Nonmyeloablative stem cell transplants. Br. J. Haematol 111:6-17
3. Childs R, Barrett J. 2002. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin. Hematol. 39(1):63-71
4. Coley W. 1896. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and bacillus proddigious with a report of 160 cases. Johns Hopkins Hosp. Bull 7:157-62
5. Rosenberg SA, Lotze MT, Muul LM, et al. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316:889-97
6. Topalian SL, Solomon D, Avis FP, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol 6:839-53
7. Rosenberg SA, Yang JC, Topalian SL, et al. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin-2. JAMA 271:907-13
8. Quesada JR, Swanson DA, Trindade A. 1983. Renal cell carcinoma: anti-tumor effects of leukocyte interferon. Cancer Res. 43:940
9. Negrier S, Escudier B, Lasset C, et al. 1998. Recombinant human interleukin-2, recombinant human interferon alpha 2a, or both in metastatic renal-cell carcinoma. N. Engl. J. Med. 338:1272-78
10. Motzer RJ, Bander NH, Nanus DM. 1996. Renal cell carcinoma. N. Engl. J. Med. 335:856
11. Gleave ME, Elhilali M, Fredet Y, et al. 1998. Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N. Engl. J. Med. 338:1265-71
12. Rosenberg SA. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-87
13. Boon T, Coulie PG, Van den Eynde B. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267-68
14. Uzzo RG, Rayman P, Bloom T. 1999. Mechanisms of apoptosis in T-cells from patients with renal cell carcinoma. Clin. Cancer Res. 5:1219-29
15. Li X, Liu J, Park JK, et al. 1994. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA binding activity: a preliminary report. Cancer Res. 54:5424-29
16. Finke JH, Zea AH, Stanley J, et al. 1993. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53:5613-16
17. Hahne M, Rimoldi D, Schroter M, et al. 1996. Melanoma cell expression of Fas(apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-66
18. Gattoni-Celli S, Kirsh K, Timpane R, et al. 1992. Beta 2 microglobulin is mutated in human colon cancer cell line (SCT) deficient in the expression of HLA class I antigens on the cell surface. Cancer Res. 52:1201-4
19. Mathe G, Amiel JL, Schwarzenberg L, et al. 1965. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 25:1525-31
20. Weiden P, Flournoy N, Thomas E, et al. 1979. Antileukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. N. Engl. J. Med. 300:1068-73
21. Weiden PL, Sullivan KM, Flournoy N, et al. 1981. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304:1529-33
22. Horowitz M, Gale RP, Sondel P, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:552-62
23. Lee M, Champlin R, Kantarjian H, et al. 1992. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation. Br. J. Haematol. 82:708-14
24. Kolb HJ, Mittermueller J, Clemm C, et al. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-65
25. Kolb HJ, Schattenberg A, Goldman JM, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-50
26. van Besien KW, de Lima M, Giralt SA, et al. 1997. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 19:977-82
27. Verdonck L, Lokhorst H, Dekker A, et al. 1996. Graft-versus-myeloma effect in 2 cases. Lancet 347:800-1
28. Jones RJ, Ambinder RF, Piantadosi S, et al. 1991. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-53
29. Heslop HE, Brenner MK, Rooney CM, et al. 1994. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331:679-80
30. Papadopoulos EB, Ladanyi M, Emanuel D, et al. 1994. Infusions of donor leukocytes to treat EBV associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185-91
31. Mehta J, Powles R, Singhal S, et al. 1996. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant. 17:371-75
32. van der Harst D, Goulmy E, Falkenburg F, et al. 1994. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83:1060-66
33. Ruggeri L, Capanni M, Casucci M, et al. 1999. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333-39
34. Appelbaum FR. 2001. Haematopoietic cell transplantation as immunotherapy. Nature 411:385-89
35. Truitt RL, Atasoylu AA. 1991. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC compatible bone marrow. Bone Marrow Transplant. 8:51-58
36. Lewalle P, Hensel N, Guimaraes A, et al. 1996. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells. Br. J. Haematol. 92:587-94
37. Faber LM, Van Luxemburg-Heijs SAP, Willemze R, et al. 1992. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J. Exp. Med. 176:1283-89
38. Goldman JM, Gale RP, Horowitz MM, et al. 1988. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann. Intern. Med. 108:806-11
39. Goulmy E. 1997. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 157:125-40
40. Warren EH, Greenberg PD, Riddell SR. 1998. Cytotoxic T-lymphocyte- defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91:2197-207
41. Dickinson AM, Wang XN, Sviland L, et al. 2002. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8:410-14
42. Mutis T, Gillespie G, Schrama E, et al. 1999. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 5:839-42
43. Huber D, Phillipp J, Fontana A, et al. 1992. Protease inhibitors interfere with transforming growth factor beta-dependent but not transforming growth factor-independent pathway of tumor cell mediated immunosuppression. J. Immunol. 148:277-84
44. Moscovitch M, Slavin S. 1984. Antitumor effects of allogeneic bone marrow transplantation in (NZB X NZW) F1 hybrids with spontaneous lymphosarcoma. J. Immunol. 132:997-1003
45. Morecki S, Moshel Y, Gelfand Y, et al. 1997. Induction of graft vs. tumor effect in a murine model of mammary carcinoma. Int. J. Cancer 71:59-63
46. Morecki S, Yacovlev E, Diab A, et al. 1998. Allogeneic cell therapy for murine mammary carcinoma. Cancer Res. 58:3891-95
47. Ladenstein R, Lasset C, Hartmann O, et al. 1994. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 14(1):37-46
48. Ben-Yosef R, Or R, Nagler A, et al. 1996. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348(9036):1242-43
49. Eibl B, Schwaighofer H, Nachbaur D, et al. 1996. Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-8
50. Ueno NT, Rondon G, Mirza NQ, et al. 1998. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. 16:986-93
51. Giralt S, Estey E, Albitar M, et al. 1997. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 89:4531-36
52. Slavin S, Nagler A, Naparastak E, et al. 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-63
53. Khouri IF, Keating M, Korbling M, et al. 1998. Transplant-lite: induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16:2817-24
54. Childs R, Clave E, Contentin N, et al. 1999. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-41
55. Sykes M, Preffer F, McAfee S, et al. 1999. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA mismatched bone-marrow transplantation. Lancet 353:1755-59
56. McSweeney PA, Niederwieser D, Shiruzu JA. 2001. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97(11):3390-400
57. Champlin R, Khouri I, Shimoni A, et al. 2000. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br. J. Haematol. 111:18-29
58. Bumpus HC. 1928. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J. Urol. 20:185
59. Finke JH, Rayman P, Hart L, et al. 1994. Characterization of TIL subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, INF-γ secretion and proliferation. J. Immunother. 15:91
60. Childs R, Clave E, Tisdale J, et al. 1999. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J. Clin. Oncol. 17(7):2044-49
61. Childs R, Chernoff A, Contentin N, et al. 2000. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343:750-58
62. Rini B, Zimmerman TM, Stadler W, et al. 2002. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. 20(8):2017-24
63. Bregni M, Dodero A, Peccatori J, et al. 2002. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99(11):4234-36
64. Hentschke P, Barkholt L, Uzunel M, et al. 2003. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant. 31(4):253-61
65. Sandmaier B, Masood N, Thompson J, et al. 2002. Fludarabine and total body irradiation (TBI), followed by allogeneic hematopoietic stem cell transplant (HSCT) as immunotherapy for metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. A1677
66. Makimoto A, Mineishi S, Tanosaki R, et al. 2001. Nonmyeloablative stem cell transplantation (NST) for refractory solid tumors. Proc. A. Soc. Clin. Oncol. 20:44
67. Childs RW, Mena OJ, Tykodi S, et al. 2002. Minor histocompatibility antigens (mHa) are expressed on renal cell carcinoma (RCC) cells and are potential targets for a graft-vs-tumor effect (GVT) following allogeneic blood stem cell transplantation (SCT). Proc. A. Soc. Clin. Oncol. 21:433a (Abstr.)
68. Warren EH, Tykodi SS, Murata M, et al. 2002. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy 4(5):441
69. Mena O, Igarashi T, Srinivasan R, et al. 2001. Immunologic mechanisms involved in the graft versus tumor effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation. Blood 98:356 (Abstr.)
70. Pedrazzoli P, Da Prada G, Giorgiani G, et al. 2002. Allogeneic blood stem cell transplantation after reduced intensity, preparative regimen - a pilot study in patients with refractory malignancies. Cancer 94(9):2409-16
71. Childs R, Bradstock K, Gottlieb DJ, et al. 2002. Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. Blood 100:429a (Abstr.)
72. Bay JO, Choufi B, Pomel C, et al. 2000. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant. 25:681-82
73. Bay JO, Fleury J, Choufi B, et al. 2002. Allogeneic hematopoietic stem cell transplantation in 2002; ovarian carcinoma: results of five patients. Bone Marrow Transplant. 30:95-102
74. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. 2003. Selective depletion of donor allo-reactive T-cells without loss of antiviral or anti-leukemic responses. Blood 102:2292-99
75. Solomon SR, Tran T, Carter CS, et al. 2002. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 4(5):395-406
76. Ruggeri L, Capanni M, Urbani E, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-100
77. Igarashi T, Srinivasan R, Wynberg J, et al. 2002. Generation of allogeneic NK cells with selective cytotoxicity to melanoma and renal cell carcinoma based on KIR-ligand incompatibility. Blood 100:73a (Abstr.)